Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of TRV130 in Patients Experiencing Moderate to Severe Acute Pain
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Jun 2014
Price :
$35
*
At a glance
- Drugs Oliceridine (Primary)
- Indications Acute pain
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Trevena
- 11 Jun 2014 According to the Trevena media release, first part of this trial is completed and second part of the study, which tests the effects of subjects metabolic capacity on TRV 130 potential duration of action is in progress.
- 11 Jun 2014 New trial record